Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 50, Issue 2, Pages 193-203
Publisher
Wiley
Online
2019-06-27
DOI
10.1111/apt.15316
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
- (2018) Mazen Noureddin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
- (2018) Shan Li et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
- (2017) Gauri Dhir et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH
- (2017) Eduardo Vilar-Gomez et al. LIVER INTERNATIONAL
- High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men
- (2017) Jieun Lee et al. PLoS One
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- (2016) Stuart McPherson et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
- (2016) Joel T. Haas et al. Annual Review of Physiology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort
- (2016) Veronica Wendy Setiawan et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
- (2016) Khalidur Rahman et al. LABORATORY INVESTIGATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis
- (2013) J. H. Hoofnagle et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- Association between metabolic syndrome and the development of non-alcoholic fatty liver disease
- (2013) YI WANG et al. Experimental and Therapeutic Medicine
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
- (2012) Donghee Kim et al. HEPATOLOGY
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
- (2012) Jinmi Lee et al. PLoS One
- C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients
- (2011) Esther Zimmermann et al. JOURNAL OF HEPATOLOGY
- Epidemiology of Non-Alcoholic Fatty Liver Disease
- (2010) Stefano Bellentani et al. DIGESTIVE DISEASES
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population
- (2009) Tomomi Kogiso et al. JOURNAL OF GASTROENTEROLOGY
- Pathogenesis of non-alcoholic fatty liver disease
- (2009) J. K. Dowman et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started